Literature DB >> 16669866

Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep.

G Virkel1, A Lifschitz, J Sallovitz, A Pis, C Lanusse.   

Abstract

Triclabendazole (TCBZ) is an halogenated benzimidazole (BZD) compound worldwide used to control immature and adult stages of the liver fluke Fasciola hepatica. The purpose of this investigation was to characterize in vitro the patterns of hepatic and ruminal biotransformation of TCBZ and its metabolites in sheep. TCBZ parent drug was metabolized into its sulphoxide (TCBZSO), sulphone (TCBZSO2) and hydroxy derivatives by sheep liver microsomes. The same microsomal fraction was also able to oxidize TCBZSO into TCBZSO2 and hydroxy-TCBZSO (HO-TCBZSO). TCBZ sulphoxidation was significantly (P < 0.001) inhibited after inactivation of the flavin-monooxygenase (FMO) system (77% inhibition) as well as in the presence of the FMO substrate methimazole (MTZ) (71% inhibition). TCBZ sulphoxidative metabolism was also reduced (24% inhibition, P < 0.05) by the cytochrome P450 inhibitor piperonyl butoxide (PB). The rate of TCBZSO conversion into TCBZSO2 was also significantly inhibited by PB (55% inhibition), MTZ (52% inhibition) and also following FMO inactivation (58% inhibition). The data reported here indicate that the FMO is the main enzymatic pathway involved in TCBZ sulphoxidation (ratio FMO/P450 = 3.83 +/- 1.63), although both enzymatic systems participate in a similar proportion in the sulphonation of TCBZSO to form the sulphone metabolite (ratio FMO/P450 = 1.31 +/- 0.23). Additionally, ketoconazole (KTZ) did not affect TCBZ sulphoxidation but decreased (66% inhibition, P < 0.05) the formation of TCBZSO2. Similarly, inhibition of TCBZSO2 production was observed after incubation of TCBZSO in the presence of KTZ and erythromycin (ETM). Conversely, thiabendazole (TBZ) and fenbendazole (FBZ) did not affect the oxidative metabolism of both incubated substrates. The sheep ruminal microflora was able to reduce the sulphoxide (TCBZSO) into the parent thioether (TCBZ). The ruminal sulphoreduction of the HO-TCBZSO derivative into HO-TCBZ was also demonstrated. The rate of sulphoreduction of HO-TCBZSO was significantly (P < 0.05) higher than that observed for TCBZSO. The metabolic approach tested here contributes to the identification of the different pathways involved in drug biotransformation in ruminant species. These findings on the pattern of hepatic and ruminal biotransformation of TCBZ and its main metabolites are a further contribution to the understanding of the pharmacological properties of widely used anthelmintics in ruminants. Comprehension of TCBZ metabolism is critical to optimize its flukicidal activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16669866     DOI: 10.1111/j.1365-2885.2006.00735.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  11 in total

1.  Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of Fasciola hepatica.

Authors:  Catherine Devine; Gerard P Brennan; Carlos E Lanusse; Luis I Alvarez; Alan Trudgett; Elizabeth Hoey; Ian Fairweather
Journal:  Parasitol Res       Date:  2010-03-25       Impact factor: 2.289

2.  Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.

Authors:  C Devine; G P Brennan; C E Lanusse; L I Alvarez; A Trudgett; E Hoey; I Fairweather
Journal:  Parasitol Res       Date:  2011-03-26       Impact factor: 2.289

3.  Erratum to: inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.

Authors:  C Devine; G P Brennan; C E Lanusse; L I Alvarez; A Trudgett; E Hoey; I Fairweather
Journal:  Parasitol Res       Date:  2011-08-14       Impact factor: 2.289

4.  Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.

Authors:  Mar Siles-Lucas; Adriano Casulli; Roberto Cirilli; David Carmena
Journal:  PLoS Negl Trop Dis       Date:  2018-04-20

5.  Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole.

Authors:  Catherine Devine; Gerard P Brennan; Carlos E Lanusse; Luis I Alvarez; Alan Trudgett; Elizabeth Hoey; Ian Fairweather
Journal:  Parasitol Res       Date:  2010-05-30       Impact factor: 2.289

6.  Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes.

Authors:  Laura Ceballos; Laura Moreno; Luis Alvarez; Laura Shaw; Ian Fairweather; Carlos Lanusse
Journal:  BMC Vet Res       Date:  2010-02-03       Impact factor: 2.741

7.  Pharmacokinetic disposition of triclabendazole in cattle and sheep; discrimination of the order and the rate of the absorption process of its active metabolite triclabendazole sulfoxide.

Authors:  N Mestorino; E A Formentini; M F Lucas; C Fernandez; P Modamio; E Mariño Hernández; J O Errecalde
Journal:  Vet Res Commun       Date:  2007-04-25       Impact factor: 2.459

8.  Albendazole enantiomeric metabolism and binding to cytosolic proteins in the liver fluke Fasciola hepatica.

Authors:  H Solana; S Scarcella; G Virkel; C Ceriani; J Rodríguez; C Lanusse
Journal:  Vet Res Commun       Date:  2008-08-26       Impact factor: 2.459

9.  Screening anthelmintic resistance to triclabendazole in Fasciola hepatica isolated from sheep by means of an egg hatch assay.

Authors:  David Robles-Pérez; José Manuel Martínez-Pérez; Francisco Antonio Rojo-Vázquez; María Martínez-Valladares
Journal:  BMC Vet Res       Date:  2015-08-28       Impact factor: 2.741

10.  Evidence of sequestration of triclabendazole and associated metabolites by extracellular vesicles of Fasciola hepatica.

Authors:  Ana Winters; Ivana Milic; Andrew Devitt; Alan Cookson; Chelsea N Davis; Peter M Brophy; Russell M Morphew
Journal:  Sci Rep       Date:  2020-08-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.